08th week of 2014 patent applcation highlights part 32 |
Patent application number | Title | Published |
20140050715 | PROTEIN HYDROLYSATES AS AGENTS FOR OVERCOMING ADDICTION - This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit. | 2014-02-20 |
20140050716 | NOVEL PROCOAGULANT MOLECULAR DECOY FOR TREATING HEMOPHILIA A OR B WITH OR WITHOUT INHIBITOR - The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor. | 2014-02-20 |
20140050717 | Methods for Treating Bleeding Disorders - A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI. | 2014-02-20 |
20140050718 | Methods and Compositions for Enhancing Intranasal Delivery of Therapeutic Agents - A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural, perivascular, or lymphatic compartment spaces is facilitated and (b) treating the patient intranasally with an active compound is disclosed. | 2014-02-20 |
20140050719 | ANTIBODIES - Antibodies that bind human β-amyloid peptide, methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture. | 2014-02-20 |
20140050720 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 2014-02-20 |
20140050721 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 - A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described. | 2014-02-20 |
20140050722 | CHIMERIC ANTI-RICIN ANTIBODY - A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain variable regions of macaque immunoglobulin. The antibody does not substantially induce any immune response against chimeric antibodies. | 2014-02-20 |
20140050723 | Cell-Penetrating Anti-DNA Antibodies and Uses Thereof Inhibit DNA Repair - Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies. | 2014-02-20 |
20140050724 | Compositions and Methods - Compositions comprising polyethylene glycol (PEG) are disclosed for the prophylaxis and/or treatment of head and neck squamous cell carcinomas (HNSCC). Methods for the prophylaxis and/or treatment of HNSCC comprising administering an effective amount of PEG are also disclosed. Also disclosed are methods and compositions for suppressing the surface expression of EGFR using PEG. | 2014-02-20 |
20140050725 | LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) - HALF LIFE EXTENDER CONSTRUCTS - The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit. | 2014-02-20 |
20140050726 | Methods and Compositions for Modulating T Cell and/or B Cell Activation - The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells. | 2014-02-20 |
20140050727 | ANTI-CD14 ANTIBODY FUSION PROTEIN - A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided. | 2014-02-20 |
20140050728 | METHODS AND COMPOSITIONS FOR INHIBITING CYCLOPHILIN D FOR THE TREATMENT AND PREVENTION OF OBESITY AND KIDNEY INDICATIONS - Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases. | 2014-02-20 |
20140050729 | METHODS FOR TREATMENT OF POLYPOSIS - The present invention relates to method for treating medical disorders mediated by mutations in the APC gene by administering an IGF1R inhibitor. Such disorders include, for example, familial adenomatous polyposis (FAP). | 2014-02-20 |
20140050730 | METHODS FOR DIAGNOSING AND TREATING NEUROENDOCRINE CANCER - The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed. | 2014-02-20 |
20140050731 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 2014-02-20 |
20140050732 | COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF MASTITIS - The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of | 2014-02-20 |
20140050733 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 2014-02-20 |
20140050734 | ANTIBODIES AGAINST THE S100P PROTEIN FOR THE TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them. | 2014-02-20 |
20140050735 | TREATMENT OF FISTULIZING CHROHN'S DISEASE - This invention is in the field of Crohn's disease. In particular, it relates to the treatment of fistulas in Crohn's disease using anti-IL-13 antibodies. The antibody may be an IgG and in particular may be the anti-IL-13 antibody 01951/G12. | 2014-02-20 |
20140050736 | CHEMOKINE RECEPTOR BINDING POLYPEPTIDES - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 2014-02-20 |
20140050737 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 2014-02-20 |
20140050738 | ANTI-TACE ANTIBODY MOLECULES AND THEIR USES - Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed. | 2014-02-20 |
20140050739 | LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS - The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof. | 2014-02-20 |
20140050740 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TISSUE FIBROSIS - Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease. | 2014-02-20 |
20140050741 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS - The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection. | 2014-02-20 |
20140050742 | METHODS AND COMPOSITIONS FOR MODULATING LYMPHANGIOGENESIS, E.G., TO TREAT TRANSPLANT REJECTION, IN A SUBJECT - Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a second antagonist for an integrin receptor. In some embodiments, the methods include enhancing survival of transplanted tissue in a subject. Aspects of the invention further include compositions, e.g., pharmaceutical compositions and kits that find use in methods of the invention. | 2014-02-20 |
20140050743 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS - The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2014-02-20 |
20140050744 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same. | 2014-02-20 |
20140050745 | Melanocortin Receptor Binding Conjugates - The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing. | 2014-02-20 |
20140050746 | AURISTATIN DRUG LINKER CONJUGATES - Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug. | 2014-02-20 |
20140050747 | Trace Elements - The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin. | 2014-02-20 |
20140050748 | MUTANT CD83 PROMOTER AND USE THEREOF - The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections. | 2014-02-20 |
20140050749 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues - The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. The exemplary polypeptides are derived from the survivin, hTERT, CYP1B1 and MART-1 antigens. | 2014-02-20 |
20140050750 | VACCINE PEPTIDE COMBINATIONS AGAINST CAT ALLERGY - The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides | 2014-02-20 |
20140050751 | Mesothelin Vaccines and Model Systems - Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line. | 2014-02-20 |
20140050752 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., membrane proteins such as vaccinia virus B5R, L1R, A33R, or A27L polypeptides). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 2014-02-20 |
20140050753 | POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES - The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein. | 2014-02-20 |
20140050754 | IMMUNOGENIC CHIKUNGUNYA VIRUS PEPTIDES - The present invention relates to immunogenic peptides of Chikungunya Virus and methods for vaccinating a subject using these peptides. Also disclosed are nucleic acids encoding these peptides and methods for their production. | 2014-02-20 |
20140050755 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 2014-02-20 |
20140050756 | NOVEL OPRF/I FUSION PROTEINS, THEIR PREPARATION AND USE - The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the | 2014-02-20 |
20140050757 | Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) - The invention provides methods and compositions for the detection and treatment of | 2014-02-20 |
20140050758 | FERMENTATION PROCESS - The present invention provides a process for periplasmic expression of a bacterial toxoid comprising the steps of: | 2014-02-20 |
20140050759 | RECOMBINANT VIRAL VECTORS AND METHODS FOR INDUCING A HETEROSUBTYPIC IMMUNE RESPONSE TO INFLUENZA A VIRUSES - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses. | 2014-02-20 |
20140050760 | Replication-Defective Arenavirus Vectors - The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases. | 2014-02-20 |
20140050761 | Crimean-Congo Hemorrhagic Fever Virus Vaccine - The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent. | 2014-02-20 |
20140050762 | DENDRITIC CELLS OBTAINED FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) - The invention relates to dendritic cells produced from human induced pluripotent stems cells (iPSC). The invention also relates to methods for making and methods of using the dendritic cells of the invention. | 2014-02-20 |
20140050763 | MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING INFECTIOUS DISEASES - The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus. | 2014-02-20 |
20140050764 | Inactivated Bacterial Cell Formulation - The invention relates to the use of lactic acid-producing bacteria to boost the immune system. | 2014-02-20 |
20140050765 | Devices and Methods for Tissue Engineering - A resorbable tissue scaffold in a glass ceramic composition forms a rigid three-dimensional porous matrix having a bioactive composition. Porosity in the form of interconnected pore space is provided by the space between the glass-ceramic fiber forming the porous matrix. Strength of the porous matrix is provided by the interconnected and bonded fiber that fuses into the rigid three-dimensional matrix. The resorbable tissue scaffold supports tissue ingrowth when implanted as a device for the repair of damaged and/or diseased bone tissue. | 2014-02-20 |
20140050766 | TISSUE ENGINEERING CONSTRUCT COMPRISING FIBRIN - A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells. | 2014-02-20 |
20140050767 | EPIDERMAL COOLING - In one aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in either the solid or liquid phase. In another aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to express the product from the aerosol container. | 2014-02-20 |
20140050768 | Copper-Containing Metal Pigments with a Metal Oxide Layer and a Plastic Layer, Method for the Production Thereof, Coating Agent and Coated Object - The invention relates to copper-containing metal pigments, wherein the copper-containing metal pigments have an elemental copper content of at least 50 wt. %, relative to the total weight of the uncoated copper-containing metal pigment, wherein the copper-containing metal pigments have at least one enveloping metal oxide layer and at least one enveloping chemically non-reactive plastic layer, wherein the sum of the amounts of the at least one chemically non-reactive plastic layer and of the at least one metal oxide layer lies in a range of from 10 to 50 wt. %, relative to the weight of the uncoated metal pigment, and the weight ratio of the at least one metal oxide layer to the at least one chemically non-reactive plastic layer lies in a range of from 1:2 to 1:20. The invention furthermore relates to a method for producing these pigments and the use thereof. | 2014-02-20 |
20140050769 | SILVER COATING PIGMENT, AND METHOD FOR PRODUCING SAME - Disclosed is a method for producing a silver (Ag) coating pigment. The method for producing a silver coating pigment according to the present invention comprises: a step of forming a tin compound pretreatment layer on the matrix surface; and a step of forming a silver coating layer on the lower portion of the tin compound pretreatment layer through a reflux and electroless plating process using a diluted solution of silver nitrate, ammonia water, a citric acid solution, and a diluted solution of potassium hydroxide. | 2014-02-20 |
20140050770 | POWDERY COSMETIC COMPOSITION - The present invention relates to a cosmetic composition comprising a pulverulent phase comprising at least one composite powder including titanium dioxide and magnesium oxide. The cosmetic composition according to the present invention is at least comparable in terms of cosmetic effects with conventional cosmetic compositions comprising a conventional composite powder including titanium dioxide and zinc oxide. Therefore, the cosmetic composition is free of any potential problems which may be caused by zinc oxide which is commonly used in conventional cosmetic compositions. | 2014-02-20 |
20140050771 | PDGF INDUCED CELL HOMING - Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising platelet-derived growth factor (PDGF). Additionally, a method of making a tissue scaffold capable of recruiting a cell is provided. | 2014-02-20 |
20140050772 | METHODS FOR TREATING CONDITIONS OF THE NAIL UNIT - The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals. | 2014-02-20 |
20140050773 | COMPOUND COMPRISING ALPHA-MSH FOR USE IN ENDODONTIC REGENERATION - The present invention concerns a compound comprising an α-MSH peptide, coupled to a polypeptide consisting of a chain of about 15 to about 400 amino acids, for use in endodontic regeneration and/or for the treatment of dental inflammatory diseases. The invention further concerns pharmaceutical compositions, in particular nanostructured compositions, comprising such a compound. | 2014-02-20 |
20140050774 | WOUND TREATMENT THERAPY - The wound treatment therapy deactivates pathogenic microorganisms within the wound environment without disrupting the cell walls. The wound treatment therapy of this invention combines the application of stabilized hypochlorous acid compound with the application of a hydrophobic wound dressing. The application of hypochlorous acid provides the initial anti-microbial agent, which disrupts and eradicates biofilm, as well as, deactivates the harmful pathogenic organisms within the wound environment. The application of the hydrophobic wound dressing, which is designed to bind harmful hydrophobic microorganisms and toxins, provides a mechanical vehicle for physically removing deactivated hydrophobic microorganisms form the wound environment with each dressing change. | 2014-02-20 |
20140050775 | Polyamine Derivatives - Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules. | 2014-02-20 |
20140050776 | NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION - The present invention is directed to methods of preventing reactivation of active and latent | 2014-02-20 |
20140050777 | Liposomal Formulations of Polymyxin and Uses Thereof - The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present invention also provides a drug delivery system that comprises a plurality of liposomes encapsulating a polymyxin B therein, where the liposomes have a minimum vesicular size of at least 500 nm. The liposomes comprising the drug delivery system are useful to increase efficacy of a treatment for a bacterial infection by increasing bioavailability and distribution of the polymyxin B within the subject. | 2014-02-20 |
20140050778 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF - The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-1 RNA frameshifting stem-loop and a (CUG)n expanded repeat stem-loop are disclosed, as are methods of treating diseases associated with these target RNA molecules. | 2014-02-20 |
20140050779 | TRANSGLUTAMINASE-2 INHIBITORS AND USES THEREOF - The present invention refers to a method of treating a disease or disorder associated with the expression of at least one transgluaminase-2 and a method of identifying a candidate transglutaminase-2 inhibitor. | 2014-02-20 |
20140050780 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF - The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention. | 2014-02-20 |
20140050781 | Use of AGR3 for Treating Cancer - Embodiments are related to processes for using an Anterior Gradient Homolog 3 (AGR3) therapeutic to treat an enhanced AGR2 expressing cancer, or its premalignant precursor, comprising administering an amount of an AGR3 therapeutic to a human patient in need thereof. | 2014-02-20 |
20140050782 | Layered Bodies, Compositions Containing Them and Processes for Producing Them - A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. | 2014-02-20 |
20140050783 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 2014-02-20 |
20140050784 | PHARMACEUTICAL COMPOSITIONS OF MEMANTINE - The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations. | 2014-02-20 |
20140050785 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. The composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method for treating or preventing hypertension by administering the pharmaceutical tablet to a patient. | 2014-02-20 |
20140050786 | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITISERS - The present invention relates to combinations of triazine derivatives and of insulin sensitisers. | 2014-02-20 |
20140050788 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein. | 2014-02-20 |
20140050789 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS - Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure. | 2014-02-20 |
20140050790 | TRITERPENE-CONTAINING OLEOGEL-FORMING AGENT, TRITERPENE-CONTAINING OLEOGEL AND METHOD FOR PRODUCING A TRITERPENE-CONTAINING OLEOGEL - The invention relates to an oleogel-forming agent which comprises at least one highly dispersed triterpene. The invention also relates to an oleogel which comprises a nonpolar liquid in an amount ranging from 80% by weight to 99% by weight based on the total weight of the oleogel and an oleogel-forming agent comprising a highly dispersed triterpene in an amount ranging from 1% by weight to 20% by weight based on the total weight of the oleogel. The invention also relates to a method for producing an oleogel. | 2014-02-20 |
20140050791 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size - The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The inventions further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention. | 2014-02-20 |
20140050792 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 2014-02-20 |
20140050793 | Novel Compositions for Inhibiting Virus Entry and Promoting Virolysis, and Methods Thereof - The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention further includes a method of causing virolysis of a virus using the compositions described therein. | 2014-02-20 |
20140050794 | PHARMACEUTICAL COMPOSITION FOR USE AS A CONTRACEPTIVE - A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. | 2014-02-20 |
20140050795 | BINDER POWDERS - The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms. | 2014-02-20 |
20140050797 | DRUG DELIVERY SYSTEMS COMPRISING SOLID SOLUTIONS OF WEALKLY BASIC DRUGS - The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 μg/mL at pH 6.8. | 2014-02-20 |
20140050798 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 2014-02-20 |
20140050799 | RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION - A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage. | 2014-02-20 |
20140050800 | METHOD OF REDUCING OXIDATIVE STRESS - Methods of ameliorating cellular oxidative stress and reducing serum cholesterol are disclosed. | 2014-02-20 |
20140050801 | GAS DISSOLVING APPARATUS - A gas dissolving apparatus that combines a gas at first pressure into a working fluid, the working present at a second pressure equal to or greater than the first pressure. The device includes a molecular mixing chamber which is designed as a truncated conical chamber located between an inlet | 2014-02-20 |
20140050802 | COMPOSITIONS AND METHODS FOR PROPHYLACTIC AND THERAPEUTIC SUPPLEMENTATION OF NUTRITION IN SUBJECTS - The present invention relates to compositions and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the composition provides a nutritional supplement with a beneficial increased supplementation of vitamin D and the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein. | 2014-02-20 |
20140050803 | COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA - Described herein are compositions and methods for the prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma or with melanoma brain tropism, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2014-02-20 |
20140050804 | COLD INFUSION PROCESS FOR FORTIFYING CORN AND/OR SOYBEANS - This invention relates to a cold infusion process for fortifying corn and/or soybeans with one or more vitamin, non-vitamin, mineral, non-mineral, botanical, hormone, herb, neutraceutical, lipid, carbohydrate, amino acid, acid, salt, prebiotic, or probiotic functional additives. This invention also discloses an infused corn and/or soybean produced by the process of infusing the corn and/or soybean at a temperature of less than about 120° F. with a solution comprising water, a bridge initiator for acid salt bias, fortifying agent(s), and an acid in a quantity sufficient to reach a pH of about 3.65. Further, this invention provides a method for the infusion of a corn and/or soybean with at least one fortifying agent at approximately room temperature. | 2014-02-20 |
20140050805 | COMPOSITION, GLUCOSE METABOLISM-IMPROVING AGENT, AND METHOD FOR IMPROVING GLUCOSE METABOLISM - A composition, including: (A) | 2014-02-20 |
20140050806 | Method, Apparatus And Kit For The Treatment Of Neurodegenerative Diseases And Impairments - A method, apparatus and kit have been discovered which regenerate with the use of odorants the connections of the neurons of the brain and central nervous system in the treatment of such person afflicted neuro-disorders caused by disease or trauma. | 2014-02-20 |
20140050807 | COMPOSITIONS CONTAINING OMEGA-3 OIL WITH AN ANTI-INFLAMMATORY AGENT AND USES THEREOF - The invention provides compositions containing omega-3 oil and at least one anti-inflammatory agent and/or at least one gastrotoxic, nephrotoxic, or hepatotoxic pharmaceutical agent. The invention further provides kits containing these compositions and methods for decreasing pain or inflammation, decreasing the symptoms of an allergic condition, and/or the gastrotoxicity, nephrotoxicity, and hepatotoxicity of a pharmaceutical agent in a subject (e.g., a human) or companion animal requiring the administration of at least one composition containing omega-3 oil. The invention also provides methods for formulating an anti-inflammatory agent to increase its absorption rate requiring the mixing of omega-3 oil with the anti-inflammatory agent and methods of concentrating an omega-3 oil. | 2014-02-20 |
20140050808 | STABILIZED FORMULATION COMPRISING OMEGA-3 FATTY ACIDS AND USE OF THE FATTY ACIDS FOR SKIN CARE AND/OR WOUND CARE - A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (Vitamin E), ascorbic acid (Vitamin C), herb extract, and a fat-soluble antioxidant. Methods for making and using the stabilized formulation are also described. | 2014-02-20 |
20140050809 | Non-Toxic Pest Repellent for Use on Humans/Animals - This invention relates generally to a non-toxic insect repellent comprising natural ingredients for application on humans and or animals. More particularly, the present invention is directed toward a non-aerosol insect repellent for application to the skin or clothing of humans and animals to repel pests found in a variety of environments, such as mosquitoes, black flies, ticks, and biting gnats. The present invention comprises the active ingredients of citronella oil, lemongrass oil, geranium oil, cedarwood oil, rosemary oil, and sesame oil that work in combination to repel pests from humans and animals over an extended period of time. The present invention also comprises an emulsifier and a preservative to provide extended shelf-life. Additionally, the present invention may optionally contain catnip oil for enhanced potency to repel biting infectious insects, particularly when used in more wilderness areas. | 2014-02-20 |
20140050810 | ANTI-OBESITY COMPOSITION COMPRISING LYCIUM CHINENSIS LEAF EXTRACT AND BETAINE AS ACTIVE INGREDIENT - Disclosed are betaine and a | 2014-02-20 |
20140050811 | DEPOSITION TOOL WITH INTERCHANGEABLE MATERIAL BAY - Technologies are provided herein for a modular deposition tool design that allows for both, the fast interchanging of materials and for easy cleaning of all wetted surfaces. A drive assembly for use in a solid freeform fabrication system, includes a drive module having a drive mechanism and a detachable material bay assembly that is detachable from the drive module. The material bay assembly includes a material bay holder, a material deposition tool, and a corresponding material bay actuation mechanism that can engage with the drive mechanism of the drive module when the material bay assembly is coupled to the drive module such that when the drive mechanism of the drive module is actuated, the material bay actuation mechanism is actuated, which causes the material deposition tool to deposit material from a material bay inserted in the material bay holder. | 2014-02-20 |
20140050812 | EXTRUSION MOLDING APPARATUS AND MANUFACTURING METHOD FOR GREEN HONEYCOMB MOLDED BODY USING SAME - The extrusion-molding device of the invention is for producing a green honeycomb molded body with a cell structure, and the device includes a housing, a screw, a die with slits, a resistance tube and a fragmenting board having through-passages through which a raw material composition passes from the upstream end side to the downstream end side. The through-passages of the fragmenting board have upstream channels composed of a plurality of flow passages extending downstream from the upstream end side, and downstream channels extending up to the downstream end side and having flow passage cross-sectional shapes different from those of the upstream channels. | 2014-02-20 |
20140050813 | Edge Seal on a Vacuum Bag Used in an Infusion Molding Process - A seal is provided on a vacuum bag used in an infusion molding process. The seal is a truncated V-shape that has convergent walls and a distal end that defines a vacuum channel in conjunction with an infusion mold. | 2014-02-20 |
20140050814 | EMBOSSING ASSEMBLY AND METHODS OF PREPARATION - The invention is directed to an embossing assembly and methods for its preparation. The assembly comprises a drum, a non-expandable insert and an embossing sleeve and it is particularly useful for the preparation of microcups used in a display device. The assembly may also comprise only a drum and an embossing sleeve. | 2014-02-20 |
20140050815 | INJECTION MOLDING MEANS - An injection molding means includes an injection mold having a cavity and an injecting port connected to the cavity; and an injection molded body, located inside the cavity of the injection mold and injected from the injecting port. The injection molded body includes a mixture of aromatic polycarbonate, profiled glass fiber (PGF), a flame retardant and a functional additive. The profiled glass fiber is a high profile ratio glass fiber (flat glass fiber). With the use of aromatic polycarbonate and PGF for thin-wall injection molding, high melt index (Melt Index, MI) of above 30 g/10 min and high flexural modulus of above 6 GPa in the case of low glass fiber proportion (20-35%), and high Melting Index value of above 50 g/10 min and high flexural modulus of above 11 GPa in the case of high glass fiber proportion (40-50%) can be reached. | 2014-02-20 |
20140050816 | Hydration System - A hydration system for providing fluid to a subject is provided, the system comprising a flexible tube for extending between a reservoir of a liquid and the mouth of the subject and having a first end for immersion in the reservoir of liquid and a second end; a holder releasably attached to a portion of the tube between the first and second ends of the tube; and a mouthpiece connected to the second end of the tube and arranged to be held in the mouth of the subject when the subject is receiving liquid from the reservoir through the tube. A holder for use in such a system is also provided. | 2014-02-20 |